Chimeric Therapeutics Ltd Cash Flow Conversion Efficiency
Chimeric Therapeutics Ltd cash flow conversion efficiency. Based on the latest financial reports, Chimeric Therapeutics Ltd (CHM) has a cash flow conversion efficiency ratio of 1.268x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-3.84 Million ≈ $-2.72 Million USD) by net assets (AU$-3.03 Million ≈ $-2.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Chimeric Therapeutics Ltd (2020–2025)
Cash flow conversion efficiency of Chimeric Therapeutics Ltd from 2020 to 2025. This chart illustrates how Chimeric Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CHM stock price for real-time trading data and today's change.
Chimeric Therapeutics Ltd Cash Flow Conversion Ratio Explained
Chimeric Therapeutics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Chimeric Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chimeric Therapeutics Ltd ranked by their cash flow conversion efficiency. Also see Chimeric Therapeutics Ltd (CHM) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Induction Healthcare Group PLC
LSE:INHC
|
-0.052x |
|
Rockfire Resources plc
LSE:ROCK
|
-0.092x |
|
Cirata plc
LSE:CRTA
|
-0.218x |
|
Slate Grocery REIT
TO:SGR-U
|
0.025x |
|
Zinc Media Group
LSE:ZIN
|
0.066x |
|
genedrive plc
LSE:GDR
|
-1.421x |
|
Viaplay Group AB Series A
ST:VPLAY-A
|
0.037x |
|
Hydrogenone Capital Growth PLC
LSE:HGEN
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Chimeric Therapeutics Ltd (2020–2025)
The table below shows the annual cash flow conversion efficiency of Chimeric Therapeutics Ltd from 2020 to 2025. Review Chimeric Therapeutics Ltd free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$1.97 Million ≈ $1.40 Million |
AU$-7.28 Million ≈ $-5.15 Million |
-3.685x | -20.75% |
| 2024-06-30 | AU$2.47 Million ≈ $1.75 Million |
AU$-7.54 Million ≈ $-5.33 Million |
-3.052x | -5.87% |
| 2023-06-30 | AU$5.66 Million ≈ $4.01 Million |
AU$-16.32 Million ≈ $-11.54 Million |
-2.882x | -463.33% |
| 2022-06-30 | AU$25.71 Million ≈ $18.19 Million |
AU$-13.15 Million ≈ $-9.31 Million |
-0.512x | -45.42% |
| 2021-06-30 | AU$25.13 Million ≈ $17.78 Million |
AU$-8.84 Million ≈ $-6.26 Million |
-0.352x | -166.12% |
| 2020-06-30 | AU$-63.91K ≈ $-45.22K |
AU$-34.01K ≈ $-24.06K |
0.532x | -- |
About Chimeric Therapeutics Ltd
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurre… Read more